<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Solventum Corp. — News on 6ix</title>
<link>https://6ix.com/company/solventum-corp</link>
<description>Latest news and press releases for Solventum Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/solventum-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c27078dffbe2df119540.webp</url>
<title>Solventum Corp.</title>
<link>https://6ix.com/company/solventum-corp</link>
</image>
<item>
<title>Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-to-report-first-quarter-fiscal-2026-earnings-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-to-report-first-quarter-fiscal-2026-earnings-on-may-5-2026</guid>
<pubDate>Tue, 14 Apr 2026 20:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.</description>
</item>
<item>
<title>Solventum to Participate in the 2026 KeyBanc Healthcare Forum</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-to-participate-in-the-2026-keybanc-healthcare-forum-9</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-to-participate-in-the-2026-keybanc-healthcare-forum-9</guid>
<pubDate>Wed, 11 Mar 2026 20:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18, 2026, beginning at approximately 10:30 a.m. EDT.</description>
</item>
<item>
<title>Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-reports-fourth-quarter-2025-financial-results-and-introduces-2026-full-year-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-reports-fourth-quarter-2025-financial-results-and-introduces-2026-full-year-guidance</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025.</description>
</item>
<item>
<title>Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-report-fourth-quarter-full-210500115</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-report-fourth-quarter-full-210500115</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast.</description>
</item>
<item>
<title>Solventum Completes Acquisition of Acera Surgical</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-completes-acquisition-acera-surgical-210500479</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-completes-acquisition-acera-surgical-210500479</guid>
<pubDate>Tue, 23 Dec 2025 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care.</description>
</item>
<item>
<title>Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy</title>
<link>https://6ix.com/company/solventum-corp/news/global-expert-panel-publishes-recommendations-210500131</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/global-expert-panel-publishes-recommendations-210500131</guid>
<pubDate>Wed, 17 Dec 2025 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) today announced the consensus recommendations of an international, multidisciplinary panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings.1 The updated recommendations, appearing in the International Wound Journal,2 underscore the evolution of ciNPT from a long-established adjunct to incision management into a therapy that can be applied in a variety of surgical pr</description>
</item>
<item>
<title>Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-earns-diamond-level-hirc-210500567</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-earns-diamond-level-hirc-210500567</guid>
<pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare. This certification validates Solventum's MedSurg segment's ability to deliver critical healthcare products consistently, even during supply disruptions to help ensure uninterrupted patient care.</description>
</item>
<item>
<title>Solventum to Participate in the 2025 Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-participate-2025-piper-sandler-210500734</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-participate-2025-piper-sandler-210500734</guid>
<pubDate>Tue, 25 Nov 2025 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Piper Sandler Healthcare Conference on Tuesday, Dec. 2, 2025, beginning at approximately 10:00 a.m. EST in New York, NY.</description>
</item>
<item>
<title>Solventum Announces $1 Billion Share Repurchase Program</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-announces-1-billion-share-140000053</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-announces-1-billion-share-140000053</guid>
<pubDate>Thu, 20 Nov 2025 14:00:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock.</description>
</item>
<item>
<title>Solventum Announces Agreement to Acquire Acera Surgical</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-announces-agreement-acquire-acera-140000405</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-announces-agreement-acquire-acera-140000405</guid>
<pubDate>Thu, 20 Nov 2025 14:00:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today it has entered into a definitive agreement to acquire Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.</description>
</item>
<item>
<title>Solventum Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-reports-third-quarter-2025-210500640</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-reports-third-quarter-2025-210500640</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Solventum to Participate in the 2025 Stifel Healthcare Conference</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-participate-2025-stifel-healthcare-210500703</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-participate-2025-stifel-healthcare-210500703</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025, beginning at approximately 11:20 a.m. EST in New York, NY.</description>
</item>
<item>
<title>Solventum Appoints Heather Knight as Chief Commercial Officer</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-appoints-heather-knight-chief-210000086</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-appoints-heather-knight-chief-210000086</guid>
<pubDate>Tue, 21 Oct 2025 21:00:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson.</description>
</item>
<item>
<title>Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-report-third-quarter-fiscal-200500693</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-report-third-quarter-fiscal-200500693</guid>
<pubDate>Thu, 16 Oct 2025 20:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast.</description>
</item>
<item>
<title>Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-announces-pricing-upsized-2-183000073</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-announces-pricing-upsized-2-183000073</guid>
<pubDate>Mon, 08 Sep 2025 18:30:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes"). The Tender Offers are being made pursuant to the terms and subject to the conditions set forth in the offer to purchase dated Aug. 22, 2025, as modified by Solventum's prior pre</description>
</item>
<item>
<title>Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-announces-early-tender-results-123000907</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-announces-early-tender-results-123000907</guid>
<pubDate>Mon, 08 Sep 2025 12:30:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap"). Solventum has amended the terms of the Tender Offers to (i) increase the Aggregate Cap from $1.75 billion to $2 billion, (ii) increase the</description>
</item>
<item>
<title>Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-completes-sale-purification-filtration-120000347</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-completes-sale-purification-filtration-120000347</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) today announced it has completed the sale of its Purification & Filtration business ("P&F") to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.0 billion in cash before customary adjustments.</description>
</item>
<item>
<title>Solventum to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-participate-upcoming-investor-conferences-200500219</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-participate-upcoming-investor-conferences-200500219</guid>
<pubDate>Thu, 28 Aug 2025 20:05:00 GMT</pubDate>
<description>Solventum (NYSE: SOLV) announced today that management will participate in fireside chats at the following investor conferences:</description>
</item>
<item>
<title>Solventum Announces $1.75 Billion Note Tender Offers</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-announces-1-75-billion-121900187</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-announces-1-75-billion-121900187</guid>
<pubDate>Fri, 22 Aug 2025 12:19:00 GMT</pubDate>
<description>Solventum Corporation (NYSE: SOLV) announced today that it has commenced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for up to $1.75 billion aggregate purchase price in cash (the "Aggregate Cap"). The Tender Offers are being made pursuant to the terms and subject to the conditions set forth in the offer to purchase dated Aug. 22, 2025 (the "Offer to Purchase").</description>
</item>
<item>
<title>Solventum Announces Pricing of Secondary Offering of Common Stock</title>
<link>https://6ix.com/company/solventum-corp/news/solventum-announces-pricing-secondary-offering-023900302</link>
<guid isPermaLink="true">https://6ix.com/company/solventum-corp/news/solventum-announces-pricing-secondary-offering-023900302</guid>
<pubDate>Thu, 14 Aug 2025 02:39:00 GMT</pubDate>
<description>Solventum Corporation (NYSE: SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any of the proceeds from the Offering. The Offering is expected to close o</description>
</item>
</channel>
</rss>